At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
Ecopipamdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years
In Brief
A Phase 2 clinical trial evaluating Ecopipam for Tourette's Syndrome. Completed, enrolled 40 participants across 11 sites.
Detailed Summary
Tourette's Syndrome is a neurological disease characterized by motor and vocal tics. It has been hypothesized that abnormal interactions of dopamine with its receptors may cause the tics. The purpose of this study is to test the hypothesis that a drug (ecopipam) that selectively blocks dopamine D1/D5 receptors can reduce the frequency and severity of the tics.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTourette's Syndrome
CountriesUnited States
CollaboratorsPsyadon Pharma
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartJun 2014
Primary CompletionDec 2019
TodayJul 2026
First PostedApr 3, 2014
Enrollment StartJun 19, 2014
Primary CompletionDec 1, 2019
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 12.2 years ago
Interventions
Ecopipamdrug
Ecopipam is a selective antagonist of the dopamine D1 receptor family.